Zacks' 7 Best Stocks for June, 2013
FREE Report for Zacks.com
Visitors Only

They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.

Today, you can see them free.

Close This Panel X

Are you a new Zacks Member or a visitor to Zacks.com?

Recent Quotes

No Recent Quote currently available

My Portfolio

My Portfolio Tracker

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Stocks on the Move 06/17/2013

Company Name Symbol %Change
GLOBAL GEOPH GGS
7.79%
STAAR SURGIC STAA
6.23%
KAPSTONE PAP KS
6.14%
HORNBECK OFF HOS
5.99%
ANIKA THERAP ANIK
5.55%

Kimberly-Clark, Booshoot Ink Deal

by Zacks Equity Research

September 11, 2012 | Comments : 0 Recommended this article: (0)

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

The world’s leading tissue manufacturer Kimberly-Clark Corporation (KMB - Analyst Report) inked a deal with the biotechnology company Booshoot, by virtue of which the former will get access to the high-yield fiber alternatives from Booshoot's proprietary bamboo propagation technology for manufacturing tissue products.

Booshoot has promised to deliver huge quantity of bamboo starts to Kimberly-Clark for testing. Initially, several species of giant bamboos will be tested if they are scalable and sustainable tree fiber alternative.

If the bamboo’s are proved viable then Kimberly-Clark can save several years that goes into growing trees before they become ready for the manufacturing of tissue products.

Booshoot scientists claim that while the Northern Softwood trees take more than 60 years to reach harvestable maturity, the new breeds of bamboo starts become harvestable in less than a decade. It is also capable of producing several times the fiber of traditional timber. These bamboos consume more carbon dioxide than normal trees, making them more eco-friendly

This technology will help Kimberly-Clark increase its productivity as well as boost sales in the near future. It will also shield the company from volatile price fluctuations in the world fiber market.

With this initiative, Kimberly-Clark will be able to save huge amount of primary wood fiber, which it sources from natural forests. This agreement will also help Kimberly-Clark to cut down usage of natural forest wood and will help it to go forward with its commitment of substituting about 50% of wood fiber taken from natural forests to alternate fiber sources by 2025.

Kimberly-Clark competes with Procter & Gamble Co. (PG - Analyst Report) and currently holds a Zacks #2 Rank (a short-term Buy rating). Over the long term, we provide a Neutral recommendation on the stock.

We are encouraged by the company’s leadership in several consumer products categories including diapers, paper goods, health care products and female personal care. Moreover, Kimberly-Clark focuses on improving its products through innovation in order to remain competitive and drive growth. These innovations are expected to help in improving brand position and market share in the consumer categories, going forward.

Email Print Share Rate Pos Rate Neg

Read/Post Comments (0) | Recommended this article (0)

Please login to Zacks.com or register to post a comment.

Zacks Research is Reported On:

Zacks Investment Research

is an A+ Rated BBB

Accredited Business.